Cambridge, United States
Design Pharmaceuticals Inc., founded in 2018, is carving out a niche in the Biotechnology, Health Care, and Pharmaceutical sectors with its innovative approach to GPCR drug discovery. With the slogan "Boundless GPCR drug discovery", the company aims to revolutionize the market by dramatically accelerating drug discovery processes.
The company leverages a cutting-edge multiplex GPCR screening platform, capable of processing over 300 cell lines with 300-fold increased throughput and 1000-fold reduced compound requirement. This platform uniquely identifies and quantifies drug target functions and potential off-target effects among diverse GPCR drug targets with impressive efficiency.
Based in the United States and backed by a $5.00M Seed Round investment from Virtus Inspire Ventures in April 2022, Design Pharmaceuticals positions itself as a pioneering entity in the domain of droplet microfluidics, promising a new era in GPCR screening and drug discovery.
